News

The open label Phase II trial will enroll up to 40 patients. TLN-4601 will be continuously administered intravenously over 21-day cycles, consisting of 14 days on treatment and

Under the terms of the agreement, Merck gains worldwide rights, except for Japan, to develop and commercialize JTT-305. Japan Tobacco (JT) will receive an upfront payment and is

UCB has taken this decision based on the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) view that the magnitude of the clinical effect

The Novel cervical interbody implant is said to be the latest product in Alphatec Spine’s pipeline that provides solutions for disorders affecting the cervical spine. The Novel cervical

In this study, patients with hormone receptor expressing advanced breast therapy whose disease had progressed on an antiestrogen therapy are being randomized to treatment with either IMC-A12 as

Concert intends to evaluate CTP-347 as a non-hormonal treatment for vasomotor symptoms or hot flashes in patients with increased risk of adverse effects due to, or contraindicated to

The round, led by Nextech Venture, included additional new investors Arcus Ventures, Innovis Investments and Eli Lilly and Company. Also participating in the financing were existing investors Alexandria

Following the company’s planned separation of its biotechnology and royalty operations, Mr Hasnain will become the president and CEO of the spin-off company, which will be known as

High-dose EPIAO is designed for the rapid restoration of hemoglobin to normal levels among cancer patients. According to the company, the 36,000 IU dosage is comparable to the